These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26098136)

  • 1. Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
    Durham PG; Zhang Y; German N; Mortensen N; Dhillon J; Mitchison DA; Fourie PB; Hickey AJ
    Mol Pharm; 2015 Aug; 12(8):2574-81. PubMed ID: 26098136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals.
    Durham PG; Young EF; Braunstein MS; Welch JT; Hickey AJ
    Int J Pharm; 2016 Dec; 514(2):384-391. PubMed ID: 27130363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
    Eedara BB; Tucker IG; Das SC
    Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
    Montgomery SA; Young EF; Durham PG; Zulauf KE; Rank L; Miller BK; Hayden JD; Lin FC; Welch JT; Hickey AJ; Braunstein M
    PLoS One; 2018; 13(9):e0204495. PubMed ID: 30261007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
    Kaewjan K; Srichana T
    Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
    Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
    Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients.
    Pham DD; Fattal E; Ghermani N; Guiblin N; Tsapis N
    Int J Pharm; 2013 Oct; 454(2):668-77. PubMed ID: 23603099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.
    Yeshwante SB; Hanafin P; Miller BK; Rank L; Murcia S; Xander C; Annis A; Baxter VK; Anderson EJ; Jermain B; Konicki R; Schmalstig AA; Stewart I; Braunstein M; Hickey AJ; Rao GG
    Mol Pharm; 2023 Sep; 20(9):4491-4504. PubMed ID: 37590399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis.
    Aekwattanaphol N; Das SC; Khadka P; Nakpheng T; Ali Khumaini Mudhar Bintang M; Srichana T
    Int J Pharm; 2024 Oct; 664():124608. PubMed ID: 39163929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
    Eedara BB; Rangnekar B; Doyle C; Cavallaro A; Das SC
    Int J Pharm; 2018 May; 542(1-2):72-81. PubMed ID: 29524618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.
    Pitner RA; Durham PG; Stewart IE; Reed SG; Cassell GH; Hickey AJ; Carter D
    J Pharm Sci; 2019 Oct; 108(10):3302-3311. PubMed ID: 31152746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment.
    Stewart IE; Durham PG; Sittenauer JM; Barreda AP; Stowell GW; Moody C; Mecham JB; Simpson C; Daily S; Maloney SE; Williams MD; Severynse-Stevens D; Hickey AJ
    Pharm Res; 2022 Dec; 39(12):3359-3370. PubMed ID: 36114362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The near future: improving the activity of rifamycins and pyrazinamide.
    Mitchison DA; Fourie PB
    Tuberculosis (Edinb); 2010 May; 90(3):177-81. PubMed ID: 20382083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment.
    Paul PK; Nakpheng T; Paliwal H; Prem Ananth K; Srichana T
    Int J Pharm; 2024 Jul; 660():124309. PubMed ID: 38848797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
    Corrêa MF; Fernandes JP
    Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.